Valsartan

WITHDRAWN · PHASE4 · Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis

Due to changes in HFpEF treatment landscape, no recruitment activities were initiated and no participants were enrolled.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.